Drug Profile
Research programme: 2-5A antisense compounds - IFN
Alternative Names: MP 351; NIH 351; spA4-anti-hTrLatest Information Update: 23 Apr 2003
Price :
$50
*
At a glance
- Originator National Institutes of Health (USA); The Cleveland Clinic Foundation
- Developer IFN
- Class Antivirals
- Mechanism of Action Cholestenone 5-alpha reductase inhibitors; RNA inhibitors; Telomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer; Respiratory syncytial virus infections
- Discontinued Acne; Alopecia
Most Recent Events
- 05 May 2001 Gemini has sold all of its assets relating to 2-5A antisense technology to IFN
- 31 Dec 2000 Discontinued - Preclinical for Acne in USA (unspecified route)
- 31 Dec 2000 Discontinued - Preclinical for Alopecia in USA (unspecified route)